Vermont Fiscal Year Ending June 30, 2026 Assessment

	Child				Adult			
	Prior Assessment Period (FY25)		Current Assessment Period (FY26)		Prior Assessment Period (FY25)		Current Assessment Period (FY26)	
Vaccine Cost Estimates								
Estimated Non-Flu Vaccine Cost Based on Current CDC Prices		$ 17,024,923		$ 20,554,647		$ 6,592,087		$ 7,989,775
Estimated Flu Vaccine Cost Based on Current CDC Prices		$ 882,734		$ 808,821		$ 648,216		$ 560,159
Estimated COVID-19 Vaccine Cost Based on Current CDC Prices		$ 2,641,660		$ 3,509,590		$ 2,514,560		$ 2,225,575
Total Estimated Vaccine Cost Based on Current CDC Prices		**$ 20,549,318**		**$ 24,873,058**		**$ 9,754,863**		**$ 10,775,508**
Provision for Vaccine Cost Increase	0.0%	$ -	0.0%	$ -	3.3%	$ 326,250	3.4%	$ 363,980
Provision for Vaccine Utilization Increase	0.5%	$ 102,747	0.5%	$ 124,365	0.5%	$ 48,774	0.5%	$ 53,878
Subtotal Estimated Vaccine Costs		**$ 20,652,064**		**$ 24,997,424**		**$ 10,129,887**		**$ 11,193,366**
Awards and Grants		$ (10,685,645)		$ (12,687,390)		$ (338,378)		$ (338,378)
Total Estimated Vaccine Costs		**$ 9,966,419**		**$ 12,310,034**		**$ 9,791,509**		**$ 10,854,988**
Total Administrative and Operating Costs		**$ 496,396**		**$ 730,864**		**$ 494,884**		**$ 688,485**
Total Reserves / Working Capital		**$ (3,177,433)**		**$ (2,100,256)**		**$ (3,883,715)**		**$ (2,063,524)**
Total Assessable Covered Lives Estimate		**56,949**		**57,411**		**346,871**		**336,125**
Assessment Calculation								
Total Assessment		**$ 7,285,382**		**$ 10,940,641**		**$ 6,402,678**		**$ 9,479,949**
Total Assessment Per Covered Life		**$ 127.93**		**$ 190.57**		**$ 18.46**		**$ 28.20**
Monthly Assessment Per Covered Life Calculated / % Change		**$ 10.66**	49.0%	**$ 15.88**		**$ 1.54**	52.8%	**$ 2.35**
Preliminary Projection								
Run Rate Monthly Assessment Per Covered Life		$ 15.31		$ 18.93		$ 2.47		$ 2.86
Preliminary Assessment Projection	0.0%	**$ 15.31**	0.0%	**$ 17.22**	3.3%	**$ 2.55**	3.4%	**$ 2.91**
Preliminary Assessment Increase		43.61%		8.42%		66.03%		23.67%
Program Metrics								
Administrative and Operational Costs as % of Vaccine Costs		4.98%		5.94%		5.05%		6.34%
CDC Vaccine Costs as % Below Private Purchase Costs		-27.55%		-27.99%		-36.63%		-41.03%

Vermont Fiscal Year Ending June 30, 2026 Assessment

	Child				Adult			
	Prior Assessment Period (FY25)		Current Assessment Period (FY26)		Prior Assessment Period (FY25)		Current Assessment Period (FY26)	
Assessment Calculation								
Estimated Vaccine Costs		$ 9,966,419		$ 12,310,034		$ 9,791,509		$ 10,854,988
Administrative and Operational Costs		$ 496,396		$ 730,864		$ 494,884		$ 688,485
Reserves / Working Capital		$ (3,177,433)		$ (2,100,256)		$ (3,883,715)		$ (2,063,524)
Total Assessment		**$ 7,285,382**		**$ 10,940,641**		**$ 6,402,678**		**$ 9,479,949**
Total Assessable Covered Lives Estimate		56,949		57,411		346,871		336,125
Total Assessment Per Covered Life		**$ 127.93**		**$ 190.57**		**$ 18.46**		**$ 28.20**
Monthly Assessment Per Covered Life Calculated / % Change		**$ 10.66**	49.0%	**$ 15.88**		**$ 1.54**	52.8%	**$ 2.35**

Preliminary Projection								
Run Rate Monthly Assessment Per Covered Life		$ 15.31		$ 18.93		$ 2.47		$ 2.86
Preliminary Assessment Projection	0.0%	**$ 15.31**	0.0%	**$ 17.22**	3.3%	**$ 2.55**	3.4%	**$ 2.91**
Preliminary Assessment Increase		43.61%		8.42%		66.03%		23.67%

Program Metrics								
Administrative and Operational Costs as % of Vaccine Costs		4.98%		5.94%		5.05%		6.34%
CDC Vaccine Costs as % Below Private Purchase Costs		-27.55%		-27.99%		-36.63%		-41.03%

Notes:

Vermont Fiscal Year Ending June 30, 2026 Assessment

Change in Assessment (from Fiscal Year Ending June 30, 2025 to Fiscal Year Ending June 30, 2026)

	Child			Adult		
	Cost	PMPM	% Change	Cost	PMPM	% Change
Fiscal Year Ending June 30, 2025	**$7,285,382**	**$ 10.66**		**$6,402,678**	**$ 1.54**	
Change In:						
Contribution Enrollees		$ (0.09)	-0.9%		$ 0.05	3.4%
Estimated Vaccine Cost	$ 4,323,741	$ 6.28	58.9%	$ 1,020,645	$ 0.25	16.3%
Provision For Vaccine Cost Increase	$ -	$ -	0.0%	$ 37,730	$ 0.01	0.7%
Provision For Vaccine Utilization Increase	$ 21,619	$ 0.03	0.3%	$ 5,103	$ -	0.0%
Awards and Grants	$ (2,001,745)	$ (2.91)	-27.3%	$ -	$ -	0.0%
Administrative Costs	$ 234,468	$ 0.34	3.2%	$ 193,601	$ 0.05	3.3%
Reserve/Working Capital	$ 1,077,177	$ 1.56	14.6%	$ 1,820,191	$ 0.45	29.3%
Fiscal Year Ending June 30, 2026	**$10,940,641**	**$ 15.88**	**49.0%**	**$9,479,949**	**$ 2.35**	**52.8%**

Vermont Fiscal Year Ending June 30, 2026 Assessment

CDC vaccine costs are 33% lower than private purchase costs (overall, child & adult).

Top 10 Vaccines - Child

Vaccine	Brandname/ Tradename	NDC	Dose Quantity	CDC Cost/ Dose	Projected Vaccine Cost	% of Total	Private Sector Cost/ Dose	Projected Private Cost	$ Savings Per Dose
Pneumococcal	Prevnar 20TM	00005-2000-10	24,000	$ 192.46	$ 4,642,135	19%	$ 274.60	$ 6,623,352	$ 82.55
HPV – Human Papillomavirus 9-valent F	Gardasil®9	00006-4121-02	16,000	$ 257.07	$ 4,133,702	17%	$ 307.61	$ 4,946,369	$ 50.79
Meningococcal Conjugate (Groups A, C, W and Y) F	MenQuadfi™	49281-0590-10	15,000	$ 114.36	$ 1,723,977	7%	$ 171.97	$ 2,592,478	$ 57.90
MMR/Varicella C	ProQuad®	00006-4171-00	7,500	$ 186.55	$ 1,406,121	6%	$ 278.16	$ 2,096,646	$ 92.07
DTaP-IPV-HIB-HEPB E	Vaxelis™	63361-0243-15	13,000	$ 103.76	$ 1,355,624	5%	$ 156.70	$ 2,047,286	$ 53.20
Respiratory Syncytial Virus (RSV)	BeyfortusTM	49281-0574-15	3,000	$ 414.75	$ 1,250,471	5%	$ 556.13	$ 1,676,738	$ 142.09
Varicella F	Varivax®	00006-4827-00	7,000	$ 151.45	$ 1,065,423	4%	$ 183.00	$ 1,287,419	$ 31.71
Respiratory Syncytial Virus (RSV)	BeyfortusTM	49281-0575-15	2,500	$ 414.75	$ 1,042,059	4%	$ 556.13	$ 1,397,282	$ 142.09
Covid-19 (Age 12 years and older)	Comirnaty®	00069-2432-10	10,000	$ 99.71	$ 1,002,086	4%	$ 136.75	$ 1,374,338	$ 37.23
Covid-19 (Age 5 years through 11 years)	COVID-19 Vaccine	59267-4438-02	12,000	$ 65.45	$ 789,327	3%	$ 77.00	$ 928,620	$ 11.61

Top 10 Vaccines - Adult

Vaccine	Brandname/ Tradename	NDC	Dose Quantity	CDC Cost/ Dose	Projected Vaccine Cost	% of Total	Private Sector Cost/ Dose	Projected Private Cost	$ Savings Per Dose
Zoster Vaccine Recombinant, Adjuvanted	Shingrix®	58160-0823-11	18,000	$ 124.56	$ 2,331,726	21%	$ 215.51	$ 4,034,310	$ 94.59
Pneumococcal	Prevnar 20™	00005-2000-10	8,000	$ 178.57	$ 1,485,702	13%	$ 274.60	$ 2,284,672	$ 99.87
Pneumococcal	Capvaxive	00006-4347-02	6,000	$ 201.68	$ 1,258,496	11%	$ 287.75	$ 1,795,560	$ 89.51
Covid-19 (Age 12 years and older)	Comirnaty®	00069-2432-10	16,000	$ 69.44	$ 1,155,482	10%	$ 136.75	$ 2,275,520	$ 70.00
Covid-19 (Age 12 years and older)	Spikevax™	80777-0110-93	14,000	$ 78.28	$ 1,139,757	10%	$ 141.80	$ 2,064,608	$ 66.06
HPV-Human Papillomavirus 9 Valent F	Gardasil®9	00006-4121-02	3,200	$ 182.79	$ 608,328	5%	$ 307.61	$ 1,023,726	$ 129.81
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular	Boostrix®	58160-0842-52	20,000	$ 28.87	$ 600,392	5%	$ 48.75	$ 1,013,917	$ 20.68
Hepatitis B Adult F	Heplisav-B™	43528-0003-05	4,000	$ 77.94	$ 324,230	3%	$ 147.63	$ 614,141	$ 72.48
Respiratory Syncytial Virus (RSV)	Abrysvo™	00069-0344-05	1,600	$ 185.09	$ 307,990	3%	$ 295.00	$ 490,880	$ 114.31
Influenza F	Flucelvax® TIV	70461-0655-03	11,250	$ 20.43	$ 233,573	2%	$ 32.45	$ 371,064	$ 12.22

Vermont Fiscal Year Ending June 30, 2026 Assessment

Comparison to Prior Period

		Cost Per Dose	Doses	Cost
Total Pediatric	Prior Period Projected	$ 83.53	247,230	$ 20,652,064
	Current Period Projected	$ 91.33	273,710	$ 24,997,424
	Variance	$ 7.79	26,480	$ 4,345,360
	% Variance	9.3%	10.7%	21.0%
Total Adult	Prior Period Projected	$ 69.00	146,820	$ 10,129,887
	Current Period Projected	$ 74.81	149,630	$ 11,193,366
	Variance	$ 5.81	2,810	$ 1,063,478
	% Variance	8.4%	1.9%	10.5%
Pediatric	Prior Period Projected	$ 106.78	160,230	$ 17,110,048
	Current Period Projected	$ 115.43	178,960	$ 20,657,420
	Variance	$ 8.65	18,730	$ 3,547,372
	% Variance	8.1%	11.7%	20.7%
Adult	Prior Period Projected	$ 90.18	76,020	$ 6,855,770
	Current Period Projected	$ 97.78	84,980	$ 8,309,366
	Variance	$ 7.60	8,960	$ 1,453,595
	% Variance	8.4%	11.8%	21.2%
Pediatric Flu	Prior Period Projected	$ 17.40	51,000	$ 887,148
	Current Period Projected	$ 17.77	45,750	$ 812,866
	Variance	$ 0.37	-5,250	$ (74,283)
	% Variance	2.1%	-10.3%	-8.4%
Adult Flu	Prior Period Projected	$ 16.27	40,500	$ 658,974
	Current Period Projected	$ 16.58	34,350	$ 569,402
	Variance	$ 0.31	-6,150	$ (89,572)
	% Variance	1.9%	-15.2%	-13.6%
Pediatric COVID-19	Prior Period Projected	$ 73.75	36,000	$ 2,654,868
	Current Period Projected	$ 71.98	49,000	$ 3,527,138
	Variance	$ (1.76)	13,000	$ 872,270
	% Variance	-2.4%	36.1%	32.9%
Adult COVID-19	Prior Period Projected	$ 86.31	30,300	$ 2,615,142
	Current Period Projected	$ 76.39	30,300	$ 2,314,598
	Variance	$ (9.92)	0	$ (300,544)
	% Variance	-11.5%	0.0%	-11.5%

Vermont Fiscal Year Ending June 30, 2026 Assessment

Summary Statistics

	Current Assessment Period									
	Dose Quantity	Vaccine Cost	Private Cost	Projected Private Cost	Stock Separation/ Other Cost	Cost Increase Assumption	Provision for Cost/ Dose Increase	Utilization Increase Assumption	Provision for Utilization Increase	Projected Vaccine Cost
Total Pediatric	**273,710**	**$ 24,873,058**	**$ 34,540,559**	**$ 34,713,262**	**$ -**	**0.0%**	**$ -**	**0.5%**	**$ 124,365**	**$ 24,997,424**
Total Adult	**149,630**	**$ 10,775,508**	**$ 18,273,715**	**$ 18,984,733**	**$ -**	**3.4%**	**$ 363,980**	**0.5%**	**$ 53,878**	**$ 11,193,366**
Pediatric	178,960	$ 20,554,647	$ 28,727,669	$ 28,871,308	$ -	0.0%	$ -	0.5%	$ 102,773	$ 20,657,420
Adult	84,980	$ 7,989,775	$ 13,209,873	$ 13,738,268	$ -	3.5%	$ 279,642	0.5%	$ 39,949	$ 8,309,366
Pediatric Flu	45,750	$ 808,821	$ 1,105,590	$ 1,111,118	$ -	0.0%	$ -	0.5%	$ 4,044	$ 812,866
Adult Flu	34,350	$ 560,159	$ 848,132	$ 862,127	$ -	1.2%	$ 6,443	0.5%	$ 2,801	$ 569,402
Pediatric COVID-19	49,000	$ 3,509,590	$ 4,707,300	$ 4,730,837	$ -	0.0%	$ -	0.5%	$ 17,548	$ 3,527,138
Adult COVID-19	30,300	$ 2,225,575	$ 4,215,710	$ 4,384,338	$ -	3.5%	$ 77,895	0.5%	$ 11,128	$ 2,314,598

	Prior Assessment Period									
	Dose Quantity	Vaccine Cost	Private Cost	Projected Private Cost	Stock Separation/ Other Cost	Cost Increase Assumption	Provision for Cost/ Dose Increase	Utilization Increase Assumption	Provision for Utilization Increase	Projected Vaccine Cost
Total Pediatric	**247,230**	**$ 20,549,318**	**$ 28,364,948**	**$ 28,506,772**	**$ -**	**0.0%**	**$ -**	**0.5%**	**$ 102,747**	**$ 20,652,064**
Total Adult	**146,820**	**$ 9,754,863**	**$ 15,392,914**	**$ 15,985,612**	**$ -**	**3.3%**	**$ 326,250**	**0.5%**	**$ 48,774**	**$ 10,129,887**
Pediatric	160,230	$ 17,024,923	$ 23,745,068	$ 23,863,794	$ -	0.0%	$ -	0.5%	$ 85,125	$ 17,110,048
Adult	76,020	$ 6,592,087	$ 10,712,344	$ 11,140,838	$ -	3.5%	$ 230,723	0.5%	$ 32,960	$ 6,855,770
Pediatric Flu	51,000	$ 882,734	$ 1,215,879	$ 1,221,959	$ -	0.0%	$ -	0.5%	$ 4,414	$ 887,148
Adult Flu	40,500	$ 648,216	$ 983,570	$ 999,894	$ -	1.2%	$ 7,517	0.5%	$ 3,241	$ 658,974
Pediatric COVID-19	36,000	$ 2,641,660	$ 3,404,000	$ 3,421,020	$ -	0.0%	$ -	0.5%	$ 13,208	$ 2,654,868
Adult COVID-19	30,300	$ 2,514,560	$ 3,697,000	$ 3,844,880	$ -	3.5%	$ 88,010	0.5%	$ 12,573	$ 2,615,142

	CDC Cost to Private Cost %	Difference Between CDC Cost/ Dose and Private Cost/ Dose	Cost Change Due to Price Change	% Change in Cost/ Dose	Change in Dose Quantity	Cost at Prior Year Dose Quantity	Cost Change Due to Dose Change	% Cost Change Due to Dose Change	Total Cost Change
Total Pediatric	**-28.0%**	**$ (2,084.55)**	**$ 785,196**	**3.8%**	**26,480**	**$ 21,334,514**	**$ 3,538,545**	**16.6%**	**$ 4,323,741**
Total Adult	**-41.0%**	**$ (2,165.96)**	**$ (176,145)**	**-1.8%**	**2,810**	**$ 9,578,718**	**$ 1,196,790**	**12.5%**	**$ 1,020,645**
Pediatric	-28.5%	$ (1,756.37)	$ 752,898	4.4%	18,730	$ 17,777,821	$ 2,776,826	15.6%	$ 3,529,724
Adult	-39.5%	$ (1,850.59)	$ 86,183	1.3%	8,960	$ 6,678,270	$ 1,311,505	19.6%	$ 1,397,688
Pediatric Flu	-26.8%	$ (92.35)	$ 18,578	2.1%	(5,250)	$ 901,312	$ (92,491)	-10.3%	$ (73,913)
Adult Flu	-34.0%	$ (104.89)	$ 8,978	1.4%	(6,150)	$ 657,194	$ (97,035)	-14.8%	$ (88,057)
Pediatric COVID-19	-25.4%	$ (235.84)	$ 13,720	0.5%	13,000	$ 2,655,380	$ 854,210	32.2%	$ 867,930
Adult COVID-19	-47.2%	$ (210.48)	$ (271,305)	-10.8%	-	$ 2,243,255	$ (17,680)	-0.8%	$ (288,985)